Suneel Gupta Protagonist Therapeutics, Inc (PTGX) insider trading activity

Suneel Gupta is Chief Development Officer of Protagonist Therapeutics, Inc. Currently has a direct ownership of 266,983 shares of PTGX, which is worth approximately $11.1 Million. The most recent transaction as insider was on Nov 26, 2024, when has been sold 19,191 shares (Common Stock) at a price of $45.5 per share, resulting in proceeds of $873,190. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 267K

45.67% 3M change

58.62% 12M change

Total Value Held $11.1 Million

Suneel Gupta Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 26 2024	SELL Open market or private sale	$873,190 $45.5 p/Share	19,191 Reduced 6.71%	266,983 Common Stock
Nov 26 2024	BUY Exercise of conversion of derivative security	$370,576 $12.17 p/Share	30,450 Added 10.22%	267,433 Common Stock
Nov 25 2024	SELL Open market or private sale	$4,762,239 $46.04 p/Share	103,437 Reduced 28.76%	256,174 Common Stock
Nov 25 2024	BUY Exercise of conversion of derivative security	$1,352,750 $7.73 p/Share	175,000 Added 32.73%	359,611 Common Stock
Feb 26 2024	SELL Payment of exercise price or tax liability	$126,447 $29.53 p/Share	4,282 Reduced 2.28%	183,285 Common Stock
Jan 09 2024	SELL Open market or private sale	$125,000 $25.0 p/Share	5,000 Reduced 2.6%	187,567 Common Stock
Jan 09 2024	BUY Exercise of conversion of derivative security	$36,900 $7.38 p/Share	5,000 Added 2.53%	192,567 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	19,250 Added 9.31%	187,567 Common Stock
Oct 19 2023	BUY Exercise of conversion of derivative security	$147,600 $7.38 p/Share	20,000 Added 10.62%	168,317 Common Stock
May 31 2023	SELL Payment of exercise price or tax liability	$108,190 $26.07 p/Share	4,150 Reduced 2.73%	148,037 Common Stock
May 31 2023	BUY Grant, award, or other acquisition	-	12,000 Added 7.31%	152,187 Common Stock
Jan 16 2023	BUY Grant, award, or other acquisition	-	20,625 Added 12.99%	138,187 Common Stock
Apr 26 2022	BUY Exercise of conversion of derivative security	$295,200 $7.38 p/Share	40,000 Added 25.39%	117,561 Common Stock
Feb 28 2022	SELL Payment of exercise price or tax liability	$15,758 $24.28 p/Share	649 Reduced 0.84%	77,007 Common Stock
Feb 15 2022	BUY Grant, award, or other acquisition	-	12,500 Added 13.86%	77,656 Common Stock
Feb 26 2021	BUY Grant, award, or other acquisition	-	12,000 Added 15.79%	63,987 Common Stock

Suneel Gupta

Chief Development Officer

Newark, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PTGX shares.

Notify only if

Value

Insider Trading

Get notified when an Protagonist Therapeutics, Inc insider buys or sells PTGX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Protagonist Therapeutics, Inc

Track Activities on PTGX

Account